NCT00372827已完成4 期
Efficacy and Safety of Timolol Maleate 0.5% Compared to Brinzolamide 1% When Added to Travoprost 0.004% in Primary Open-angle Glaucoma or Ocular Hypertension
适应症
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 245
- 试验地点
- 2
- 主要终点
- Mean diurnal intraocular pressure at month 3
研究概览
简要总结
The purpose of the study is to compare the efficacy and safety of Timolol 0.5% solution to Brinzolamide 1% each given twice daily when added to Travoprost 0.004% given each evening.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients who are treated with any prostaglandin analogue monotherapy (excluding unoprostone) and who have an intraocular pressure between 19 and 32 mmHg at 08:00 hours.
排除标准
- •Under 18 years
结局指标
主要结局
Mean diurnal intraocular pressure at month 3
次要结局
- Visual acuity, Slit lamp biomicroscopy and adverse events during 3 months.
- Individual intraocular pressures measured at 08:00, 12:00 and 16:00 at month 3.
- Reduction from baseline in mean diurnal intraocular pressure and individual timepoints.
研究者
研究点 (2)
Loading locations...
相似试验
已完成
不适用
The Efficacy and Safety of Brinzolamide 1%/Timolol 0.5% Fixed Combination Versus Dorzolamide 1%/Timolol 0.5Subjects with open angle glaucoma or ocular hypertension currently on PGA monotherapyJPRN-UMIN000017569Alcon Japan Ltd.190
已完成
2 期
Efficacy, Safety and Pharmacokinetics of Topical Timolol in Infants With Infantile Hemangioma (IH)Infantile HemangiomaNCT02913612Kanecia Obie Zimmerman105
已完成
3 期
Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients With Glaucoma or Ocular HypertensionOcular HypertensionNCT00332436Allergan586
已完成
2 期
Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients With Glaucoma or Ocular HypertensionOcular HypertensionNCT00332345Allergan73
已完成
3 期
Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients With Glaucoma or Ocular HypertensionOcular HypertensionNCT00332384Allergan573